Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

556 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP-RCC study.
Blas L, Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tanegashima T, Tokunaga S, Eto M; SNiP-RCC Investigators. Blas L, et al. Among authors: ohyama c. Int J Urol. 2023 Sep;30(9):788-796. doi: 10.1111/iju.15265. Epub 2023 Aug 1. Int J Urol. 2023. PMID: 37528632
Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial.
Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tanegashima T, Tokunaga S, Eto M; SNiP-RCC investigators. Shiota M, et al. Among authors: ohyama c. Cancer Immunol Immunother. 2023 Jun;72(6):1903-1915. doi: 10.1007/s00262-023-03367-w. Epub 2023 Feb 2. Cancer Immunol Immunother. 2023. PMID: 36729213 Free PMC article.
Diversity in treatment modalities of Stage II/III urothelial cancer in Japan: sub-analysis of the multi-institutional national database of the Japanese Urological Association.
Koie T, Ohyama C, Fujimoto H, Nishiyama H, Miyazaki J, Hinotsu S, Kikuchi E, Sakura M, Inokuchi J, Hara T; Cancer Registration Committee of the Japanese Urological Association; Ohyama C, Nishiyama H, Fujisawa M, Uemura H, Fujimoto H, Suzuki K, Eto M, Hara I, Matsubara A, Nonomura N, Nakanishi H, Koie T, Kanayama H, Miki T, Fukumori T, Naito S; Cancer Registration Committee of the Japanese Urological Association. Koie T, et al. Among authors: ohyama c. Jpn J Clin Oncol. 2016 May;46(5):468-74. doi: 10.1093/jjco/hyw005. Epub 2016 Feb 6. Jpn J Clin Oncol. 2016. PMID: 26851754
Utility of the Age Discrepancy between Frailty-Based Biological Age and Expected Life Age in Patients with Urological Cancers.
Togashi K, Hatakeyama S, Soma O, Okita K, Fujita N, Tanaka T, Noro D, Horiguchi H, Uemura N, Iwane T, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C. Togashi K, et al. Among authors: ohyama c. Cancers (Basel). 2022 Dec 17;14(24):6229. doi: 10.3390/cancers14246229. Cancers (Basel). 2022. PMID: 36551713 Free PMC article.
Impact of an optimized surveillance protocol based on the European Association of Urology substratification on surveillance costs in patients with primary high-risk non-muscle-invasive bladder cancer.
Fujita N, Hatakeyama S, Okita K, Momota M, Tobisawa Y, Yoneyama T, Yamamoto H, Ito H, Yoneyama T, Hashimoto Y, Yoshikawa K, Ohyama C. Fujita N, et al. Among authors: ohyama c. PLoS One. 2023 Feb 10;18(2):e0275921. doi: 10.1371/journal.pone.0275921. eCollection 2023. PLoS One. 2023. PMID: 36763567 Free PMC article.
Effect of HLA Genotype on Anti-PD-1 Antibody Treatment for Advanced Renal Cell Carcinoma in the SNiP-RCC Study.
Tanegashima T, Shiota M, Fujiyama N, Narita S, Habuchi T, Fukuchi G, Takamatsu D, Oda Y, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tokunaga S, Eto M. Tanegashima T, et al. Among authors: ohyama c. J Immunol. 2024 May 17:ji2300308. doi: 10.4049/jimmunol.2300308. Online ahead of print. J Immunol. 2024. PMID: 38758119
Impact of severe acute kidney injury on short-term mortality in urosepsis.
Fujita N, Momota M, Soma O, Noro D, Mikami J, Miura Y, Ito H, Yoneyama T, Hashimoto Y, Yoshikawa K, Ohyama C, Hatakeyama S. Fujita N, et al. Among authors: ohyama c. World J Urol. 2024 May 8;42(1):301. doi: 10.1007/s00345-024-05018-w. World J Urol. 2024. PMID: 38717511
556 results